These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 28156160)
1. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Qiao H; Fang D; Chen J; Sun Y; Kang C; Di L; Li J; Chen Z; Chen J; Gao Y Drug Deliv; 2017 Nov; 24(1):233-242. PubMed ID: 28156160 [TBL] [Abstract][Full Text] [Related]
2. Galactosamine-modified PEG-PLA/TPGS micelles for the oral delivery of curcumin. Sun S; Du X; Fu M; Khan AR; Ji J; Liu W; Zhai G Int J Pharm; 2021 Feb; 595():120227. PubMed ID: 33484915 [TBL] [Abstract][Full Text] [Related]
3. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and in vivo delivery of curcumin by copolymeric mPEG-PCL micelles. Kheiri Manjili H; Ghasemi P; Malvandi H; Mousavi MS; Attari E; Danafar H Eur J Pharm Biopharm; 2017 Jul; 116():17-30. PubMed ID: 27756682 [TBL] [Abstract][Full Text] [Related]
5. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Hua S; Marks E; Schneider JJ; Keely S Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453 [TBL] [Abstract][Full Text] [Related]
6. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease. Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873 [TBL] [Abstract][Full Text] [Related]
8. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease. Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374 [TBL] [Abstract][Full Text] [Related]
9. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369 [TBL] [Abstract][Full Text] [Related]
10. An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice. Li S; Jin M; Wu Y; Jung S; Li D; He N; Lee MS Drug Deliv; 2021 Dec; 28(1):1120-1131. PubMed ID: 34121560 [TBL] [Abstract][Full Text] [Related]
11. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): Formulation development, characterization and pharmacological evaluation. Kesharwani SS; Ahmad R; Bakkari MA; Rajput MKS; Dachineni R; Valiveti CK; Kapur S; Jayarama Bhat G; Singh AB; Tummala H J Control Release; 2018 Nov; 290():165-179. PubMed ID: 30142410 [TBL] [Abstract][Full Text] [Related]
12. Dual functional matrix metalloproteinase-responsive curcumin-loaded nanoparticles for tumor-targeted treatment. Guo F; Fu Q; Jin C; Ji X; Yan Q; Yang Q; Wu D; Gao Y; Hong W; Li A; Yang G Drug Deliv; 2019 Dec; 26(1):1027-1038. PubMed ID: 31691601 [TBL] [Abstract][Full Text] [Related]
13. Comb-like amphiphilic copolymers bearing acetal-functionalized backbones with the ability of acid-triggered hydrophobic-to-hydrophilic transition as effective nanocarriers for intracellular release of curcumin. Zhao J; Wang H; Liu J; Deng L; Liu J; Dong A; Zhang J Biomacromolecules; 2013 Nov; 14(11):3973-84. PubMed ID: 24107101 [TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Melero A; Draheim C; Hansen S; Giner E; Carreras JJ; Talens-Visconti R; Garrigues TM; Peris JE; Recio MC; Giner R; Lehr CM Eur J Pharm Biopharm; 2017 Oct; 119():361-371. PubMed ID: 28709903 [TBL] [Abstract][Full Text] [Related]
15. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. Yadav VR; Suresh S; Devi K; Yadav S J Pharm Pharmacol; 2009 Mar; 61(3):311-21. PubMed ID: 19222903 [TBL] [Abstract][Full Text] [Related]
16. Development of Chitosan-Based pH-Sensitive Polymeric Micelles Containing Curcumin for Colon-Targeted Drug Delivery. Woraphatphadung T; Sajomsang W; Rojanarata T; Ngawhirunpat T; Tonglairoum P; Opanasopit P AAPS PharmSciTech; 2018 Apr; 19(3):991-1000. PubMed ID: 29110292 [TBL] [Abstract][Full Text] [Related]
17. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482 [TBL] [Abstract][Full Text] [Related]
18. Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis. Wang QS; Wang GF; Zhou J; Gao LN; Cui YL Int J Pharm; 2016 Dec; 515(1-2):176-185. PubMed ID: 27713029 [TBL] [Abstract][Full Text] [Related]
19. Improved uptake and therapeutic intervention of curcumin via designing binary lipid nanoparticulate formulation for oral delivery in inflammatory bowel disorder. Sharma M; Sharma S; Wadhwa J Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):45-55. PubMed ID: 30663410 [TBL] [Abstract][Full Text] [Related]
20. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Zeeshan M; Ali H; Khan S; Khan SA; Weigmann B Int J Pharm; 2019 Mar; 558():201-214. PubMed ID: 30615925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]